Cardiology · Coronary Artery DiseaseTrial Updateclinicalmid-term

Bayer's Study on Nitroglycerin and Nurandociguat Safety in CAD Patients

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Bayer5 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/26/2026, 6:33:02 PM

Assessment confidence: 53% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing clinical trial by Bayer aims to evaluate the safety and interaction of nitroglycerin and nurandociguat in patients with coronary artery disease. The outcomes could significantly influence treatment protocols and market positioning for nurandociguat, especially in the context of CAD and CKD management. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 7 ranked evidence items (2 high-relevance).

Strategic Assessment

Portfolio teams should monitor the outcomes of this trial as it may influence the positioning of nurandociguat in the market. The strongest clinical anchor is A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease (ClinicalTrials.gov), entity match (bayer). In cardiology, 3 regulatory and 0 competitive items passed relevance filtering for Bayer.

Competitive Pressure

The most relevant competitive pressure comes from This study could provide insights into the combined use of two vasodilators, potentially impacting treatment protocols for CAD and CKD..

Regulatory Outlook

Regulatory risk is concentrated around Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA). Sub-indication match (cardiology). The trial's findings may affect future regulatory submissions and labeling for nurandociguat, particularly regarding its safety profile when used in combination with nitroglycerin.

Key Risks

Elevated medium regulatory exposure for Bayer could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) could weigh on Bayer through agency review timelines and labeling constraints if follow-through weakens.
Clinical risk from ClinicalTrials.gov (A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease) could weigh on Bayer through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Positive trial results could enhance nurandociguat's market positioning and increase its adoption among healthcare providers, potentially impacting revenue streams for Bayer.
Upside for Bayer may improve if Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA) delivers favorable follow-through.
Upside for Bayer may improve if Nephrotoxic medication burden and drug-related problems in patients with chronic kidney disease using SGLT2 inhibitors. (PubMed) delivers favorable follow-through.
Upside for Bayer may improve if A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should monitor the outcomes of this trial as it may influence the positioning of nurandociguat in the market.

What Would Change This Assessment

This becomes more urgent if Key milestones include interim results on safety and efficacy, as well as any reported adverse events during the trial.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026
FDAhigh relevance
Sub-indication match (cardiology)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
Hepatitis C Medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to Rare Occurrence of Serious Liver Injury in Some patients with Advanced Liver Disease
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Office of New Drugs Custom Medical Queries (OCMQs) for Safety Signal Detection in Clinical Trial Data - 06/23/2026
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Lessons Learned from our Roundtable with Rare Disease Advocates
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Opportunities for patients and the public to be involved in the work of the MHRA
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Compounding Safety Information: Quinacrine Hydrochloride
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease
ClinicalTrials.govmedium relevance
Entity match (bayer)
FDA document
View source
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
ClinicalTrials.govmedium relevance
Entity match (chronic kidney disease)
FDA document
View source
Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Di
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Phase 3 Study of Radiprodil in GRIN-related Neurodevelopmental Disorder Initiated
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Safety and efficacy of ashwagen (a standardized withania somnifera extract) in stress and anxiety with hypertension and associated cardiometabolic risk factors: a randomized, placebo-controlled trial.
PubMedhigh relevance
Sub-indication match (cardiology)
FDA document
View source
Nephrotoxic medication burden and drug-related problems in patients with chronic kidney disease using SGLT2 inhibitors.
PubMedmedium relevance
Entity match (chronic kidney disease)
FDA document
View source
Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Bayer
coronary artery disease
chronic kidney disease

Commercial impact

medium

Positive trial results could enhance nurandociguat's market positioning and increase its adoption among healthcare providers, potentially impacting revenue streams for Bayer.

Regulatory impact

medium

The trial's findings may affect future regulatory submissions and labeling for nurandociguat, particularly regarding its safety profile when used in combination with nitroglycerin.

What to watch

Key milestones include interim results on safety and efficacy, as well as any reported adverse events during the trial.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.